Empresa Kancera AB (publ) Nasdaq Stockholm
Acciones
SE0015658570
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 01/03/22 |
Director of Finance/CFO | 75 | - | |
Johan Schultz
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/13 |
Martin Norin
COO | Chief Operating Officer | 65 | 01/01/10 |
Thomas Olin
CTO | Chief Tech/Sci/R&D Officer | 66 | 05/05/10 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 01/09/23 |
Niclas Brynne
PRN | Corporate Officer/Principal | 63 | 01/09/16 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Chairman | 63 | 05/05/10 | |
Director/Board Member | 66 | 01/01/16 | |
Håkan Mellstedt
FOU | Founder | 82 | 28/04/10 |
Thomas Olin
CTO | Chief Tech/Sci/R&D Officer | 66 | 05/05/10 |
Director/Board Member | 72 | 28/05/12 | |
Director/Board Member | 58 | 30/05/18 | |
Petter Brodin
BRD | Director/Board Member | - | 26/05/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 121 186 228 | 55 214 243 ( 45,56 %) | 0 | 45,56 % |
Información de la empresa
Kancera AB
Karolinska Institutet Science Park Nanna Svartz Väg 4
171 65, Solna
+46 8 50 12 60 80
http://www.kancera.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+15,82 % | 121 mil M | |
+20,35 % | 113 mil M | |
+17,47 % | 26,02 mil M | |
-25,31 % | 19,39 mil M | |
-19,51 % | 15,91 mil M | |
-19,67 % | 15,09 mil M | |
-46,87 % | 15,06 mil M | |
+62,55 % | 14,93 mil M | |
+6,34 % | 13,85 mil M |